Kyverna Therapeutics, Inc. KYTX 深 沪
等待开盘 10-05 09:30:00 美东时间
6.22
-0.300
-4.60%
华盛通- 最 高6.7537
- 今 开6.62
- 成交量 118.30万股
- 最 低 6.17
- 昨 收 6.52
- 总市值 3.85亿
- 52周最高 13.67
- 市盈率 静 --
- 换手率 1.91%
- 52周最低 6.17
- 委 比 58.45%
- 总股本 6184.34万
- 历史最高 35.06
- 量 比 1.22
- 振 幅 8.95%
- 历史最低 1.78
- 每 手 1
- 风险率 0.99%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kyverna Therapeutics Therapy Delivers Sustained Relief in Rare Neurological Conditions
Kyverna Therapeutics Inc. (NASDAQ:KYTX) announced 12-month topline results from two trials evaluating its miv-cel cell therapy in neurological autoimmune conditions. The late-stage clinical immunology company highlighted strong, durable efficacy data in patients with stiff-person syndrome and genera...
09-24 23:44
Kyverna Therapeutics Q2 EPS $(0.63) Beats $(0.68) Estimate
Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.68) by 7.35 percent. This is a 35.05 percent increase over losses of $(0.97) per share from the same period last year.
08-12 04:18
Kyverna Therapeutics Announces Manufacturing Agreement For Both U.S. Commercial And Global Clinical Supply Of Miv-Cel, Kyverna’s Autologous CD19-Directed CAR T-Cell Therapy
Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, and ElevateBio, a technology-driven advanced therapy contract development and manufacturing organization (CDMO), today announced a manufacturing ...
07-27 20:04
美股大行评级 | 火爆！24家大行集体上调派拓网络目标价，最高370美元；大摩上调美光目标价从520美元升至1050美元
火爆！24家大行集体上调派拓网络目标价，最高370美元；大摩上调美光目标价从520美元升至1050美元；犹他美容(ULTA)惨遭12家大行下调目标价>>
06-04 11:36
Kyverna Therapeutics Reports Phase 1 Data For Miv-Cel In Rheumatoid Arthritis, Showing Deep B-Cell Depletion And Potential Immune Reset At Week 36
Majority of patients met the American College of Rheumatology improvement criteria (ACR70) response by Week 36Single-dose of miv-cel delivered deep B-cell depletion with evidence of immune resetMiv-cel continues to
06-03 20:09
美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
JP Morgan Maintains Overweight on Kyverna Therapeutics, Lowers Price Target to $29
JP Morgan analyst Brian Cheng maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight and lowers the price target from $30 to $29.
05-13 23:33
Kyverna Therapeutics Q1 EPS $(0.66) Beats $(0.73) Estimate
Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(0.73) by 9.59 percent. This is a 35.92 percent increase over losses of $(1.03) per share
05-13 04:40
美股大行评级 | 潜在涨幅15%！15家大行集体上调德州仪器目标价；CSX运输、拉姆研究、金沙集团、马斯可木业、Vertiv Holdings等获多家大行上调目标价
今日重点评级关注：花旗：维持Pegasystems"买入"评级，目标价从70美元升至71美元；巴克莱：维持曼哈顿联合软件"超配"评级，目标价从236美元升至239美元
04-24 12:10
